Optimization of Schistosomiasis treatment in Tanzania
- Conditions
- MalariaSschistosomiasis
- Registration Number
- PACTR201612001914353
- Lead Sponsor
- Muhumbili University of Health and Allied Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- All
- Target Recruitment
- 600
1. School children aged 5-15 years, both male and females 2. Live primarily in a study village/area. 3. School children confirmed schistosomiasis positive by urine filtration test for urinary schistosomiasis and kato-katz for intestinal schistosomiasis 4. School children confirmed malaria positive or negative by microscopy 5.Parent/s has/have consented for child to recruited in this study 6. The child has assented to participate 7. No Known or documented sensitivity to any of the drugs under test
1. Patients without diagnosis of Schistosomiasis (tested negative for schistosomiasis) 2.A recent PZQ treatment before entry to the study(2 months) 3. Presence of danger signs and symptoms of severe malaria according to WHO criteria 4. Prior treatment of malaria within 14 days of study enrollement 5. Patient receiving any medication known to affect cytochrome P450 within 14 days of the study enrollement 6. Pregnant women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Schistosomiasis treatment outcome defined as presence or absence of eggs in urine or stool at 1 month and 2moths period netween the new intervention(PZq+DHP) and PZQ alone arms
- Secondary Outcome Measures
Name Time Method DHP and PZQ interaction (drug level);Pharmacogenetics of PZQ ad DHP for the presence of single nucleotide polymorphisim (SNPs);day 7 piperaquine plasma concetration + malaria treatment outcome using DHP in the presence of PZQ;safety + tolerability of the new intervention (adverse events)